# Privia Health Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/PRVA/privia-health-reports-first-quarter-2026-financial-results
Ticker: PRVA
Company: Privia Health
Source: Privia Health
Published: 2026-05-07 10:00 EST
Original Source URL: https://ir.priviahealth.com
## Summary

Strong First Quarter Performance and Operating Execution Reiterated Full-Year 2026 Guidance Reflects Continued Momentum ARLINGTON, Va., May 07, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the first quarter ended March 31, 2026.

## Article Body
Strong First Quarter Performance and Operating Execution Reiterated Full-Year 2026 Guidance Reflects Continued Momentum ARLINGTON, Va., May 07, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the first quarter ended March 31, 2026.
## Recent Company News
- 2026-05-27 13:00 EST — [Privia Health Enters New Jersey](https://biopharmsignal.com/news/PRVA/privia-health-enters-new-jersey) — Source: Privia Health
- 2026-05-07 10:00 EST — [Privia Health Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/PRVA/privia-health-reports-first-quarter-2026-financial-results) — Source: Privia Health
- 2026-04-08 13:00 EST — [Privia Health to Report First Quarter 2026 Results on Thursday, May 7](https://biopharmsignal.com/news/PRVA/privia-health-to-report-first-quarter-2026-results-on-thursday-may-7) — Source: Privia Health
- 2026-03-24 13:00 EST — [Privia Health Earns 2026 HFMA MAP Award for Revenue Cycle Excellence](https://biopharmsignal.com/news/PRVA/privia-health-earns-2026-hfma-map-award-for-revenue-cycle-excellence) — Source: Privia Health
- 2026-02-26 11:00 EST — [Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results](https://biopharmsignal.com/news/PRVA/privia-health-reports-fourth-quarter-and-full-year-2025-financial-results) — Source: Privia Health
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)